

# Early High-Titer Plasma Therapy to Prevent Severe Cov

New England Journal of Medicine

384, 610-618

DOI: [10.1056/nejmoa2033700](https://doi.org/10.1056/nejmoa2033700)

Citation Report

#	ARTICLE	IF	CITATIONS
1	How should we use convalescent plasma therapies for the management of COVID-19?. <i>Blood</i> , 2021, 137, 1573-1581.	0.6	29
2	Use of convalescent plasma for COVID-19 in India: A review & practical guidelines. <i>Indian Journal of Medical Research</i> , 2021, 153, 64.	0.4	5
3	Therapeutic Use of Convalescent Plasma in COVID-19 Infected Patients with Concomitant Hematological Disorders. <i>Clinical Hematology International</i> , 2021, 3, 77.	0.7	8
4	Absence of Vaccine-enhanced Disease With Unexpected Positive Protection Against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by Inactivated Vaccine Given Within 3 Days of Virus Challenge in Syrian Hamster Model. <i>Clinical Infectious Diseases</i> , 2021, 73, e719-e734.	2.9	16
5	Convalescent COVID-19 plasma. <i>Scripta Medica</i> , 2021, 52, 1-5.	0.0	0
6	Passive Immunity Should and Will Work for COVID-19 for Some Patients. <i>Clinical Hematology International</i> , 2021, 3, 47.	0.7	4
8	COVID-19-associated thrombotic microangiopathy (TMA). <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2021, 32, 307-314.	0.1	0
9	Viral infections in lung transplantation. <i>Journal of Thoracic Disease</i> , 2021, 13, 6673-6694.	0.6	9
10	Clinical and Virologic Effectiveness of Remdesivir Treatment for Severe Coronavirus Disease 2019 (COVID-19) in Korea: a Nationwide Multicenter Retrospective Cohort Study. <i>Journal of Korean Medical Science</i> , 2021, 36, e83.	1.1	24
11	Convalescent Plasma Therapy in SARS-COV-2 Infection, Experience in Tucum�n Argentina: An Observational Study. <i>Frontiers in Medical Case Reports</i> , 2021, 02, .	0.0	0
12	Emergency response for evaluating SARS-CoV-2 immune status, seroprevalence and convalescent plasma in Argentina. <i>PLoS Pathogens</i> , 2021, 17, e1009161.	2.1	62
13	Collaborative Response to COVID-19 Pandemic, and Development of Treatment Guidelines. <i>Infection and Chemotherapy</i> , 2021, 53, 151.	1.0	4
14	Has Convalescent Plasma Therapy Hesitancy Increased COVID-19 Mortality?. <i>South Asian Journal of Cancer</i> , 2021, 10, 42-45.	0.2	1
15	Severe Acute Respiratory Syndrome Coronavirus 2: Manifestations of Disease and Approaches to Treatment and Prevention in Humans. <i>Comparative Medicine</i> , 2021, 71, 342-358.	0.4	3
16	Standardized Two-Step Testing of Antibody Activity in COVID-19 Convalescent Plasma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
17	Treatment of Severe COVID-19 with Convalescent Plasma in Bronx, NYC. <i>JCI Insight</i> , 2021, 6, .	2.3	36
18	Treatment Strategies for COVID-19 in Pregnancy: Short Review of Current Recommendations. <i>Open Journal of Obstetrics and Gynecology</i> , 2021, 11, 823-829.	0.1	1
19	Limited window for donation of convalescent plasma with high live-virus neutralizing antibody titers for COVID-19 immunotherapy. <i>Communications Biology</i> , 2021, 4, 267.	2.0	25

#	ARTICLE	IF	CITATIONS
22	(A Little) Clarity on Convalescent Plasma for Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 666-668.	13.9	80
26	Characteristics, Treatment, and Outcomes of Patients With Severe or Life-threatening COVID-19 at a Military Treatment Facility—A Descriptive Cohort Study. <i>Military Medicine</i> , 2022, 187, e1043-e1046.	0.4	3
31	Breadth and function of antibody response to acute SARS-CoV-2 infection in humans. <i>PLoS Pathogens</i> , 2021, 17, e1009352.	2.1	56
32	Facing up to the COVID-19 pandemic in Argentina. <i>Nature Immunology</i> , 2021, 22, 264-265.	7.0	9
33	Monoclonal antibodies for treating COVID-19. <i>Cleveland Clinic Journal of Medicine</i> , 2021, , .	0.6	16
34	COVID-19 vaccines for patients with cancer: benefits likely outweigh risks. <i>Journal of Hematology and Oncology</i> , 2021, 14, 38.	6.9	87
36	A matched cohort study of convalescent plasma therapy for COVID-19. <i>Journal of Clinical Apheresis</i> , 2021, 36, 523-532.	0.7	14
37	Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency—Three consecutive cases and review of the literature. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2022, 40, 507-516.	0.3	21
38	A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic. <i>Frontiers in Immunology</i> , 2021, 12, 631139.	2.2	117
39	Adjunctive Nutraceutical Therapies for COVID-19. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1963.	1.8	33
40	Covid-19: India's slow moving treatment guidelines are misleading and harming patients. <i>BMJ</i> , The, 2021, 372, n278.	3.0	9
41	COVID-19: Reasons for Guarded Optimism. <i>Pharmaceutical Medicine</i> , 2021, 35, 67-69.	1.0	0
43	Retrospective analysis of 426 donors of a convalescent collective after mild COVID-19. <i>PLoS ONE</i> , 2021, 16, e0247665.	1.1	5
44	The Evidence for High-Titer Convalescent Plasma in SARS-CoV-2. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 790-792.	0.3	8
47	An automated approach to determine antibody endpoint titers for COVID-19 by an enzyme-linked immunosorbent assay. <i>Immunohematology</i> , 2021, 37, 33-43.	0.2	0
48	Development and Characterization of Inhaled Ethanol as a Novel Pharmacological Strategy Currently Evaluated in a Phase II Clinical Trial for Early-Stage SARS-CoV-2 Infection. <i>Pharmaceutics</i> , 2021, 13, 342.	2.0	8
49	Prone positioning for severe ARDS in a postpartum COVID-19 patient following caesarean section. <i>BMJ Case Reports</i> , 2021, 14, e240385.	0.2	3
50	Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization by Intravenous Immunoglobulins Produced From Plasma Collected During the 2020 Pandemic. <i>Journal of Infectious Diseases</i> , 2022, 226, 1357-1361.	1.9	30

#	ARTICLE	IF	CITATIONS
51	Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults. <i>Trials</i> , 2021, 22, 221.	0.7	14
52	Preanalytical Issues and Cycle Threshold Values in SARS-CoV-2 Real-Time RT-PCR Testing: Should Test Results Include These?. <i>ACS Omega</i> , 2021, 6, 6528-6536.	1.6	63
56	Efficacy and Safety of Convalescent Plasma for COVID-19: A Systematic Review and Meta-analysis. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2021, 37, 347-365.	0.3	16
57	Current evidence for COVID-19 therapies: a systematic literature review. <i>European Respiratory Review</i> , 2021, 30, 200384.	3.0	37
58	Convalescent hyperimmune plasma in patients with hematologic malignancies and severe COVID-19 infections. <i>Leukemia and Lymphoma</i> , 2021, 62, 1284-1286.	0.6	1
59	Ophthalmological Considerations for COVID-19 Vaccination in Patients with Inflammatory Eye Diseases and Autoimmune Disorders. <i>Ophthalmology and Therapy</i> , 2021, 10, 201-209.	1.0	21
62	Convalescent plasma and hyperimmune globulin therapy in COVID-19. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 309-315.	1.3	10
64	Protracted SARS-CoV-2 pneumonia with rituximab treatment: About two cases. <i>Journal of Medical Virology</i> , 2021, 93, 4141-4144.	2.5	7
68	Blockers of the SARS-CoV-2 3a Channel Identified by Targeted Drug Repurposing. <i>Viruses</i> , 2021, 13, 532.	1.5	18
70	Endogenously Produced SARS-CoV-2 Specific IgG Antibodies May Have a Limited Impact on Clearing Nasal Shedding of Virus during Primary Infection in Humans. <i>Viruses</i> , 2021, 13, 516.	1.5	5
71	Lessons learned in the collection of convalescent plasma during the COVID-19 pandemic. <i>Vox Sanguinis</i> , 2021, 116, 872-879.	0.7	8
72	COVID-19 convalescent plasma; time for goal directed therapy?. <i>Transfusion</i> , 2021, 61, 1654-1656.	0.8	2
73	Antibody kinetics and clinical course of COVID-19 a prospective observational study. <i>PLoS ONE</i> , 2021, 16, e0248918.	1.1	13
76	Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19. <i>Viruses</i> , 2021, 13, 436.	1.5	24
77	Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. <i>European Respiratory Journal</i> , 2021, 57, 2100048.	3.1	152
79	COVID-19 convalescent plasma: Interim recommendations from the AABB. <i>Transfusion</i> , 2021, 61, 1313-1323.	0.8	40
80	High neutralizing potency of swine glycohumanized polyclonal antibodies against SARS-CoV-2. <i>European Journal of Immunology</i> , 2021, 51, 1412-1422.	1.6	21
81	Use of convalescent serum reduces severity of COVID-19 in nonhuman primates. <i>Cell Reports</i> , 2021, 34, 108837.	2.9	23

#	ARTICLE	IF	CITATIONS
82	Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT). <i>Clinical Microbiology and Infection</i> , 2021, 27, 389-395.	2.8	37
83	High-titre anti-SARS-CoV-2 convalescent plasma donation after donors'™ vaccination. <i>Vox Sanguinis</i> , 2021, 116, 930-931.	0.7	5
84	An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?. <i>Frontiers in Pharmacology</i> , 2021, 12, 632677.	1.6	65
86	The first 12 months of COVID-19: a timeline of immunological insights. <i>Nature Reviews Immunology</i> , 2021, 21, 245-256.	10.6	325
87	Anticoagulant Treatment of COVID-19 as Early as Possible—Sulodexide and Perspectives. <i>Thrombosis and Haemostasis</i> , 2021, 121, 849-853.	1.8	5
88	Consensus Recommendations for Intramuscular COVID-19 Vaccination in Patients with Hemophilia. <i>Hamostaseologie</i> , 2021, 41, 190-196.	0.9	8
90	The story of an extraordinary year: Challenges and opportunities in responding to Covid-19. <i>Transfusion and Apheresis Science</i> , 2021, 60, 103092.	0.5	3
91	Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. <i>Nature Reviews Immunology</i> , 2021, 21, 395-404.	10.6	223
92	Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis. <i>JMIR Public Health and Surveillance</i> , 2021, 7, e25500.	1.2	19
93	Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19. <i>Lancet Microbe</i> , The, 2021, 2, e138.	3.4	45
94	Algorithm for Individual Prediction of COVID-19-Related Hospitalization Based on Symptoms: Development and Implementation Study. <i>JMIR Public Health and Surveillance</i> , 2021, 7, e29504.	1.2	6
95	Severe Acute Respiratory Syndrome Coronavirus 2 Convalescent Plasma Versus Standard Plasma in Coronavirus Disease 2019 Infected Hospitalized Patients in New York: A Double-Blind Randomized Trial*. <i>Critical Care Medicine</i> , 2021, 49, 1015-1025.	0.4	59
96	Preservation of neutralizing antibody function in COVID-19 convalescent plasma treated using a riboflavin and ultraviolet light-based pathogen reduction technology. <i>Vox Sanguinis</i> , 2021, 116, 1076-1083.	0.7	11
98	Lassa Virus Treatment Options. <i>Microorganisms</i> , 2021, 9, 772.	1.6	22
99	Convalescent plasma therapy - a silver lining for COVID-19 management?. <i>Hematology, Transfusion and Cell Therapy</i> , 2021, 43, 201-211.	0.1	3
100	Exponential increase in neutralizing and spike specific antibodies following vaccination of COVID-19 convalescent plasma donors. <i>Transfusion</i> , 2021, 61, 2099-2106.	0.8	27
101	Misleading clinical evidence and systematic reviews on ivermectin for COVID-19. <i>BMJ Evidence-Based Medicine</i> , 2022, 27, 156-158.	1.7	40
103	Case Report: Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma Therapy With Full Clinical Recovery. <i>Frontiers in Immunology</i> , 2021, 12, 613502.	2.2	13

#	ARTICLE	IF	CITATIONS
104	COVID-19, a tale of two peaks: patients' characteristics, treatments, and clinical outcomes. <i>Internal and Emergency Medicine</i> , 2021, 16, 1629-1639.	1.0	5
105	Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	58
106	A Phase II Study on the Use of Convalescent Plasma for the Treatment of Severe COVID-19- A Propensity Score-Matched Control Analysis. <i>Microorganisms</i> , 2021, 9, 806.	1.6	12
107	COVID-19 convalescent plasma therapy: hit fast, hit hard!. <i>Vox Sanguinis</i> , 2021, 116, 935-942.	0.7	25
108	Safety and Efficacy of Convalescent Plasma in Elderly COVID-19 Patients: The RESCUE Trial. <i>Mayo Clinic Proceedings Innovations, Quality &amp; Outcomes</i> , 2021, 5, 403-412.	1.2	19
109	Convalescent Plasma and Coronavirus Disease 2019: Time for Reassessment*. <i>Critical Care Medicine</i> , 2021, 49, 1182-1186.	0.4	3
110	Clinical predictors of SARS-CoV-2 neutralizing antibody titers in COVID-19 convalescents: Implications for convalescent plasma donor recruitment. <i>European Journal of Haematology</i> , 2021, 107, 24-28.	1.1	16
111	Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma. <i>MBio</i> , 2021, 12, .	1.8	57
112	Personalized collection of plasma from healthy donors: A randomized controlled trial of a novel technology-enabled nomogram. <i>Transfusion</i> , 2021, 61, 1789-1798.	0.8	11
114	Suggested guidelines for convalescent plasma therapy for the treatment of COVID-19. <i>Hematology, Transfusion and Cell Therapy</i> , 2021, 43, 212-213.	0.1	16
115	The Principles of Antibody Therapy for Infectious Diseases with Relevance for COVID-19. <i>MBio</i> , 2021, 12, .	1.8	62
116	The time to offer treatments for COVID-19. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 505-518.	1.9	20
117	The Three Pillars of COVID-19 Convalescent Plasma Therapy. <i>Life</i> , 2021, 11, 354.	1.1	17
118	RBD-specific polyclonal F(ab) <sub>2</sub> fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial. <i>EClinicalMedicine</i> , 2021, 34, 100843.	3.2	41
120	We stand ready   Blood collection organizations and the COVID-19 pandemic. <i>Transfusion</i> , 2021, 61, 1345-1349.	0.8	2
121	Convalescent plasma to treat COVID-19: Following the Argentinian lead. <i>Transfusion and Apheresis Science</i> , 2021, 60, 103161.	0.5	1
122	Impact of COVID-19 in patients with lymphoid malignancies. <i>World Journal of Virology</i> , 2021, 10, 97-110.	1.3	11
123	Comparative immune profiling of acute respiratory distress syndrome patients with or without SARS-CoV-2 infection. <i>Cell Reports Medicine</i> , 2021, 2, 100291.	3.3	17

#	ARTICLE	IF	CITATIONS
125	Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses. <i>Science Advances</i> , 2021, 7, .	4.7	113
126	Response to Aviv et al. <i>Journal of Infectious Diseases</i> , 2021, 224, 559-561.	1.9	5
127	Are We Forgetting About IgA? A Re-examination of Coronavirus Disease 2019 Convalescent Plasma. <i>Transfusion</i> , 2021, 61, 1740-1748.	0.8	16
128	Ventilator-induced barotrauma in critically ill patients with COVID-19: a retrospective observational study. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2021, 11, 304-310.	0.4	4
129	A Framework for Outpatient Infusion of Antispik Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1250-1261.	1.4	45
130	Virological Characterization of Critically Ill Patients With COVID-19 in the United Kingdom: Interactions of Viral Load, Antibody Status, and B.1.1.7 Infection. <i>Journal of Infectious Diseases</i> , 2021, 224, 595-605.	1.9	20
131	The Association Between Convalescent Plasma Treatment and Survival of Patients with COVID-19. <i>Journal of General Internal Medicine</i> , 2021, 36, 2528-2531.	1.3	10
132	Potential use of convalescent plasma for SARS-CoV-2 prophylaxis and treatment in immunocompromised and vulnerable populations. <i>Expert Review of Vaccines</i> , 2022, 21, 877-884.	2.0	24
133	Physicians at the crossroad of prognosis and faith: practical help communicating with patients and families during the COVID-19 pandemic. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2021, 11, 293-295.	0.4	0
134	Rapid Clinical and Radiological Improvement in a Patient with Severe COVID-19 Infection Treated with Convalescent Plasma. <i>Reports</i> , 2021, 4, 15.	0.2	0
135	Constraints and challenges in convalescent plasma collection amidst the Covid 19 pandemic-strategies and recommendations to overcome these. <i>Transfusion Clinique Et Biologique</i> , 2021, 28, 175-179.	0.2	6
136	Therapeutic mechanisms of mesenchymal stem cells in acute respiratory distress syndrome reveal potentials for Covid-19 treatment. <i>Journal of Translational Medicine</i> , 2021, 19, 198.	1.8	15
137	Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy. <i>American Journal of Hematology</i> , 2021, 96, 934-944.	2.0	110
139	The Relevance of Monoclonal Antibodies in the Treatment of COVID-19. <i>Vaccines</i> , 2021, 9, 557.	2.1	10
140	Convalescent plasma in patients hospitalised with COVID-19. <i>Lancet, The</i> , 2021, 397, 2024-2025.	6.3	18
141	Feasibility of convalescent plasma therapy in severe COVID-19 patients with persistent SARS-CoV-2 viremia. <i>Journal of Medical Virology</i> , 2021, 93, 5594-5598.	2.5	4
142	Overview of SARS-CoV-2 infection in adults living with HIV. <i>Lancet HIV, the</i> , 2021, 8, e294-e305.	2.1	129
144	Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial.. <i>EClinicalMedicine</i> , 2021, 35, 100849.	3.2	146

#	ARTICLE	IF	CITATIONS
145	Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. <i>Lancet</i> , The, 2021, 397, 2049-2059.	6.3	391
146	Predictors for inpatient mortality during the first wave of the SARS-CoV-2 pandemic: A retrospective analysis. <i>PLoS ONE</i> , 2021, 16, e0251262.	1.1	6
148	Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival. <i>Nature Communications</i> , 2021, 12, 2670.	5.8	297
149	Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy. , 2021, 9, e002392.		9
152	Convalescent Plasma Efficacy in Life-Threatening COVID-19 Patients Admitted to the ICU: A Retrospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2113.	1.0	7
153	Características clínicas, laboratoriales y predictores de mortalidad de pacientes con COVID-19 internados en el Hospital Nacional. <i>Revista Científica Ciencias De La Salud</i> , 2021, 3, 26-37.	0.1	0
154	Convalescent plasma from people vaccinated after COVID-19 infection. <i>Lancet Microbe</i> , The, 2021, 2, e171-e172.	3.4	9
156	Remdesivir for Early COVID-19 Treatment of High-Risk Individuals Prior to or at Early Disease Onset—Lessons Learned. <i>Viruses</i> , 2021, 13, 963.	1.5	11
157	A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. <i>Vaccine</i> , 2021, 39, 2791-2799.	1.7	185
158	Determinants of IgG antibodies kinetics after severe and critical COVID-19. <i>Journal of Medical Virology</i> , 2021, 93, 5416-5424.	2.5	13
159	Convalescent plasma therapy and mortality in COVID-19 patients admitted to the ICU: a prospective observational study. <i>Annals of Intensive Care</i> , 2021, 11, 73.	2.2	9
160	The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1262-1275.	1.4	129
161	Characteristics of coronavirus disease 19 convalescent plasma donors and donations in the New York metropolitan area. <i>Transfusion</i> , 2021, 61, 2374-2383.	0.8	6
162	High-titer convalescent plasma therapy for coronavirus disease 2019 and mortality. <i>Transfusion</i> , 2021, 61, 1988-1990.	0.8	4
163	Prolonged Coronavirus Disease 2019 in a Patient With Rheumatoid Arthritis on Rituximab Therapy. <i>Journal of Infectious Diseases</i> , 2021, 224, 557-559.	1.9	6
164	Prospects of Neutralizing Nanobodies Against SARS-CoV-2. <i>Frontiers in Immunology</i> , 2021, 12, 690742.	2.2	22
165	On the road to ending the COVID-19 pandemic: Are we there yet?. <i>Virology</i> , 2021, 557, 70-85.	1.1	38
166	Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. <i>The Cochrane Library</i> , 2021, 2021, CD013600.	1.5	109



#	ARTICLE	IF	CITATIONS
168	Management of COVID-19 pneumonia in a child with NEMO deficiency. Immunologic Research, 2021, 69, 391-393.	1.3	5
169	Efficacy and safety of convalescent plasma therapy in SARS-CoV2 patients on hemodialysis. Hemodialysis International, 2021, 25, 515-522.	0.4	6
170	Early Convalescent Plasma Therapy and Mortality Among US Veterans Hospitalized With Nonsevere COVID-19: An Observational Analysis Emulating a Target Trial. Journal of Infectious Diseases, 2021, 224, 967-975.	1.9	14
171	Mounting evidence for immunizing previously infected subjects with a single dose of SARS-CoV-2 vaccine. Journal of Clinical Investigation, 2021, 131, .	3.9	16
173	Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products. Clinical Immunology, 2021, 227, 108723.	1.4	31
174	Human CD4+ T cells specific for dominant epitopes of SARS-CoV-2 Spike and Nucleocapsid proteins with therapeutic potential. Clinical and Experimental Immunology, 2021, 205, 363-378.	1.1	34
175	Future developments in the prevention, diagnosis and treatment of COVID-19. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2021, 73, 56-80.	1.4	4
176	Potential predictors of outcomes among hospitalized COVID-19 patients treated with convalescent plasma: a single-center study. Journal of Community Hospital Internal Medicine Perspectives, 2021, 11, 464-469.	0.4	0
177	Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature, 2021, 596, 417-422.	13.7	549
179	Perspectives on passive antibody therapy and peptide-based vaccines against emerging pathogens like SARS-CoV-2. Germs, 2021, 11, 287-305.	0.5	2
180	Heterogeneity in COVID-19 Convalescent Plasma Clinical Trials. Clinical Pharmacology and Therapeutics, 2022, 111, 995-1000.	2.3	5
181	Qualifying coronavirus disease 2019 convalescent plasma donors in Israel. Vox Sanguinis, 2021, , .	0.7	7
182	Plasma Therapy to Prevent Severe Covid-19 in Older Adults. New England Journal of Medicine, 2021, 384, e104.	13.9	22
183	Emergency Use Authorizations (EUAs) Versus FDA Approval: Implications for COVID-19 and Public Health. American Journal of Public Health, 2021, 111, 1065-1069.	1.5	7
184	Use of convalescent plasma in COVID-19 patients with immunosuppression. Transfusion, 2021, 61, 2503-2511.	0.8	70
186	A novel scoring system for selecting the target patients of COVID-19 convalescent plasma therapy: A hypothesis. Transfusion Clinique Et Biologique, 2022, 29, 89-91.	0.2	5
187	Hyperimmune anti-COVID-19 IVIG (C-IVIG) treatment in severe and critical COVID-19 patients: A phase I/II randomized control trial. EclinicalMedicine, 2021, 36, 100926.	3.2	49
188	COVID-19 convalescent plasma donor recruitment experience from the perspective of a hospital transfusion medicine service. Transfusion, 2021, 61, 2213-2215.	0.8	0

#	ARTICLE	IF	CITATIONS
189	Is the Endothelium the Missing Link in the Pathophysiology and Treatment of COVID-19 Complications?. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 547-560.	1.3	37
190	Advances in Neutralization Assays for SARS-CoV-2. <i>Scandinavian Journal of Immunology</i> , 2021, 94, e13088.	1.3	40
191	Science's Response to CoVID-19. <i>ChemMedChem</i> , 2021, 16, 2288-2314.	1.6	15
192	Adjunctive treatment with high-titre convalescent plasma in severely and critically ill COVID-19 patients â€“ a safe but futile intervention. A comparative cohort study. <i>Infectious Diseases</i> , 2021, 53, 820-829.	1.4	7
194	Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence. <i>Frontiers in Medicine</i> , 2021, 8, 684151.	1.2	50
195	Hyperimmune plasma infusion in an immunocompromised Covid-19 patient previously treated for follicular lymphoma. <i>Monaldi Archives for Chest Disease</i> , 2021, , .	0.3	6
196	COVID-19 and Cardiovascular Diseases: Challenges and Solutions. <i>Cardiology Research</i> , 2021, 12, 149-155.	0.5	2
197	Convalescent blood plasma (CBP) donated by recovered COVID-19 patients â€“ A comment. <i>Transfusion and Apheresis Science</i> , 2021, 60, 103108.	0.5	0
198	Real-world Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients With Early COVID-19. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab331.	0.4	47
199	Convalescent Plasma for Pregnant Women with COVID-19: A Systematic Literature Review. <i>Viruses</i> , 2021, 13, 1194.	1.5	9
200	Systematic review and meta-analysis of randomised controlled trials testing the safety and efficacy of convalescent plasma in the treatment of coronavirus disease 2019 (<scp>COVID</scp> â€“19): Evidenceâ€base for practise and implications for research. <i>Transfusion Medicine</i> , 2021, 31, 409-420.	0.5	12
201	Convalescent plasma use in the USA was inversely correlated with COVID-19 mortality. <i>ELife</i> , 2021, 10, .	2.8	38
203	Convalescent plasma therapy in patients with moderate-to-severe COVID-19: A study from Indonesia for clinical research in low- and middle-income countries. <i>EClinicalMedicine</i> , 2021, 36, 100931.	3.2	21
204	Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN-Î². <i>Journal of Clinical Immunology</i> , 2021, 41, 1425-1442.	2.0	39
205	Humoral and Cellular Immune Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants and Human Coronaviruses After Single BNT162b2 Vaccination. <i>Clinical Infectious Diseases</i> , 2021, 73, 2000-2008.	2.9	30
206	SARS-CoV-2 Antiviral Therapy. <i>Clinical Microbiology Reviews</i> , 2021, 34, e0010921.	5.7	64
207	SARS-CoV-2 Neutralizing Antibody Responses towards Full-Length Spike Protein and the Receptor-Binding Domain. <i>Journal of Immunology</i> , 2021, 207, 878-887.	0.4	30
208	Effectiveness of COVID-19 Convalescent Plasma Infusion Within 48 Hours of Hospitalization With SARS-CoV-2 Infection. <i>Cureus</i> , 2021, 13, e16746.	0.2	0

#	ARTICLE	IF	CITATIONS
209	COVID-19 and earlier pandemics, sepsis, and vaccines: A historical perspective. <i>Journal of Intensive Medicine</i> , 2021, 1, 4-13.	0.8	9
210	Transplant of SARS-CoV-2â€infectious Living Donor Liver: Case Report. <i>Transplantation Direct</i> , 2021, 7, e721.	0.8	16
211	Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaques. <i>PLoS Pathogens</i> , 2021, 17, e1009688.	2.1	16
212	<scp>COVID</scp>â€19 convalescent plasma cohort study: Evaluation of the association between both donor and recipient neutralizing antibody titers and patient outcomes. <i>Transfusion</i> , 2021, 61, 2295-2306.	0.8	8
213	Early antibody responses associated with survival in COVID19 patients. <i>PLoS Pathogens</i> , 2021, 17, e1009766.	2.1	13
214	SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants. <i>PLoS Medicine</i> , 2021, 18, e1003656.	3.9	109
216	Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial. <i>BMC Infectious Diseases</i> , 2021, 21, 635.	1.3	75
217	Predicting the efficacy of COVID-19 convalescent plasma donor units with the Lumit Dx anti-receptor binding domain assay. <i>PLoS ONE</i> , 2021, 16, e0253551.	1.1	5
218	Efficacy of Different Types of Therapy for COVID-19: A Comprehensive Review. <i>Life</i> , 2021, 11, 753.	1.1	14
219	Burden of nosocomial COVID-19 in Wales: results from a multicentre retrospective observational study of 2508 hospitalised adults. <i>Thorax</i> , 2021, 76, 1246-1249.	2.7	25
220	Heart Transplantation Complicated by COVID-19 Infection. <i>Annals of Thoracic Surgery</i> , 2022, 113, e267-e269.	0.7	4
222	Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). <i>Infectious Diseases and Therapy</i> , 2021, 10, 1837-1885.	1.8	28
223	Is there a role for immune-enhancing therapies for acutely ill patients with coronavirus disease 2019?. <i>Current Opinion in Critical Care</i> , 2021, 27, 480-486.	1.6	2
224	Contemporary narrative review of treatment options for COVID â€19. <i>Respirology</i> , 2021, 26, 745-767.	1.3	12
225	Durability of Immunity to SARS-CoV-2 and Other Respiratory Viruses. <i>Trends in Microbiology</i> , 2021, 29, 648-662.	3.5	43
226	A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	131
227	What we learned in the past year in managing our COVID-19 patients in intensive care units?. <i>World Journal of Critical Care Medicine</i> , 2021, 10, 81-101.	0.8	5
228	COVID-19: Failure of the DisCoVeRy Clinical Trial, and Nowâ€New Hopes?. <i>Pharmaceuticals</i> , 2021, 14, 664.	1.7	3

#	ARTICLE	IF	CITATIONS
229	Immunopathogenesis of Different Emerging Viral Infections: Evasion, Fatal Mechanism, and Prevention. <i>Frontiers in Immunology</i> , 2021, 12, 690976.	2.2	4
230	Treating the endotheliopathy of <scp>SARS-CoV-2</scp> infection with plasma: Lessons learned from optimized trauma resuscitation with blood products. <i>Transfusion</i> , 2021, 61, S336-S347.	0.8	2
231	Characteristics of High-Titer Convalescent Plasma and Antibody Dynamics After Administration in Patients With Severe Coronavirus Disease 2019. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab385.	0.4	3
232	Convalescent Plasma Reduces Endogenous Antibody Response in COVID-19: A Retrospective Cross-Sectional Study. <i>Turkish Journal of Haematology</i> , 2021, 38, 321-324.	0.2	1
233	Evaluation of the convalescent plasma therapy effectiveness and the factors that influence the therapeutic outcome in hospitalized COVID-19 patients: A retrospective cohort study. <i>F1000Research</i> , 0, 10, 650.	0.8	0
234	The safety of <scp>COVID-19</scp> convalescent plasma donation: A <scp>multi-institutional</scp> donor hemovigilance study. <i>Transfusion</i> , 2021, 61, 2668-2676.	0.8	9
235	Upper age limits for convalescent plasma donation and treatment of <scp>COVID-19</scp> patients: A further marker of ageism. <i>Transfusion</i> , 2021, 61, 2799-2800.	0.8	1
236	On-admission SARS-CoV-2 RNAemia as a single potent predictive marker of critical condition development and mortality in COVID-19. <i>PLoS ONE</i> , 2021, 16, e0254640.	1.1	16
237	SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data. <i>Eurosurveillance</i> , 2021, 26, .	3.9	31
238	Convalescent plasma in the management of COVID-19 pneumonia. <i>European Journal of Internal Medicine</i> , 2021, 89, 121-123.	1.0	1
239	Coronavirus disease 2019 in children. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 500-509.	1.3	8
240	Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19. <i>PLoS ONE</i> , 2021, 16, e0254453.	1.1	27
241	Patient-blood management for COVID19 convalescent plasma therapy: relevance of affinity and donor recipient differences in concentration of neutralizing antibodies. <i>Clinical Microbiology and Infection</i> , 2021, 27, 987-992.	2.8	6
242	Impact of the COVID-19 pandemic on the management of chronic noninfectious respiratory diseases. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1035-1048.	1.0	14
243	Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. <i>European Respiratory Journal</i> , 2022, 59, 2101471.	3.1	55
244	Early and persistent viral clearance in COVID-19 patients treated with convalescent plasma. <i>Transfusion Clinique Et Biologique</i> , 2021, 28, 309-310.	0.2	2
245	India and management of COVID-19: A case study on published guidelines. <i>Drug Discoveries and Therapeutics</i> , 2021, 15, 171-179.	0.6	0
246	SARS-CoV-2 spike protein: pathogenesis, vaccines, and potential therapies. <i>Infection</i> , 2021, 49, 855-876.	2.3	61

#	ARTICLE	IF	CITATIONS
247	Has plasma therapy failed in Covid-19 or we have failed in using it properly in India?â€“Lessons learned through the pandemic. <i>Transfusion Clinique Et Biologique</i> , 2022, 29, 92-93.	0.2	0
248	Successful early treatment combining remdesivir with high-titer convalescent plasma among COVID-19-infected hematological patients. <i>Hematological Oncology</i> , 2021, 39, 715-720.	0.8	9
249	Pathogenesis and treatment of cytokine storm in COVID-19. <i>Turkish Journal of Biology</i> , 2021, 45, 372-389.	2.1	18
250	Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. <i>JAMA Oncology</i> , 2021, 7, 1167.	3.4	149
251	Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. <i>European Respiratory Journal</i> , 2022, 59, 2101724.	3.1	38
252	COVID-19 vaccination: The impact on the selection criteria of the convalescent plasma donors. <i>Transfusion Clinique Et Biologique</i> , 2021, 28, 308-309.	0.2	2
253	CONVALESCENT plasma for COVID-19: A meta-analysis of clinical trials and real-world evidence. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13663.	1.7	24
254	Effect of time and titer in convalescent plasma therapy for COVID-19. <i>IScience</i> , 2021, 24, 102898.	1.9	16
255	Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	72
256	Minimally instrumented SHERLOCK (miSHERLOCK) for CRISPR-based point-of-care diagnosis of SARS-CoV-2 and emerging variants. <i>Science Advances</i> , 2021, 7, .	4.7	189
257	Efficacy of convalescent plasma for treatment of COVID-19 in Uganda. <i>BMJ Open Respiratory Research</i> , 2021, 8, e001017.	1.2	30
259	COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?. <i>Transfusion Clinique Et Biologique</i> , 2021, 28, 264-270.	0.2	23
260	COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors. <i>Viruses</i> , 2021, 13, 1594.	1.5	31
261	Should timing be considered before abandoning convalescent plasma in covid-19? Results from the Turkish experience. <i>Transfusion and Apheresis Science</i> , 2021, 60, 103238.	0.5	2
263	Improvements in Severe Acute Respiratory Syndrome Coronavirus 2 Testing Cascade in the United States: Data From Serial Cross-sectional Assessments. <i>Clinical Infectious Diseases</i> , 2021, , .	2.9	5
264	mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects. <i>Vaccines</i> , 2021, 9, 918.	2.1	40
265	Convalescent plasma for COVID-19: a meta-analysis, trial sequential analysis, and meta-regression. <i>British Journal of Anaesthesia</i> , 2021, 127, 834-844.	1.5	13
266	High-titre convalescent plasma therapy for an immunocompromised patient with systemic lupus erythematosus with protracted SARS-CoV-2 infection. <i>BMJ Case Reports</i> , 2021, 14, e244853.	0.2	7

#	ARTICLE	IF	CITATIONS
267	Peripheral B Cell Deficiency and Predisposition to Viral Infections: The Paradigm of Immune Deficiencies. <i>Frontiers in Immunology</i> , 2021, 12, 731643.	2.2	19
269	Experience of Treating COVID-19 With Remdesivir and Convalescent Plasma in a Resource-Limited Setting: A Prospective, Observational Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab391.	0.4	11
270	Early Convalescent Plasma for High-Risk Outpatients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 385, 1951-1960.	13.9	177
271	A Review of Treatment and Prevention of Coronavirus Disease 2019 among Solid Organ Transplant Recipients. <i>Viruses</i> , 2021, 13, 1706.	1.5	9
272	Comparability of six different immunoassays measuring SARS-CoV-2 antibodies with neutralizing antibody levels in convalescent plasma: From utility to prediction. <i>Transfusion</i> , 2021, 61, 2837-2843.	0.8	29
273	Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice. <i>Military Medical Research</i> , 2021, 8, 47.	1.9	88
274	Is convalescent plasma futile in COVID-19? A Bayesian re-analysis of the RECOVERY randomized controlled trial. <i>International Journal of Infectious Diseases</i> , 2021, 109, 114-117.	1.5	38
275	Current advances in transfusion medicine 2020: A critical review of selected topics by the AABB Clinical Transfusion Medicine Committee. <i>Transfusion</i> , 2021, 61, 2756-2767.	0.8	1
276	Asymptomatic COVID-19 in the elderly: dementia and viral clearance as risk factors for disease progression.. <i>Gates Open Research</i> , 2021, 5, 143.	2.0	1
277	Cross-Neutralizing Activity Against SARS-CoV-2 Variants in COVID-19 Patients: Comparison of 4 Waves of the Pandemic in Japan. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab430.	0.4	18
278	Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 385, 777-789.	13.9	712
279	Interferon-gamma release assay testing to assess COVID-19 vaccination response in a SARS-CoV-2 seronegative patient on rituximab: a case report. <i>International Journal of Infectious Diseases</i> , 2021, 110, 229-231.	1.5	15
280	Successful treatment of COVID-19 infection with convalescent plasma in B-cell-depleted patients may promote cellular immunity. <i>European Journal of Immunology</i> , 2021, 51, 2478-2484.	1.6	8
281	Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 209-221.	4.6	233
282	Progress and challenges in mass spectrometry-based analysis of antibody repertoires. <i>Trends in Biotechnology</i> , 2022, 40, 463-481.	4.9	23
283	Convalescent Plasma in a Patient with Protracted COVID-19 and Secondary Hypogammaglobulinemia Due to Chronic Lymphocytic Leukemia: Buying Time to Develop Immunity?. <i>Infectious Disease Reports</i> , 2021, 13, 855-864.	1.5	9
284	Antibody therapy for COVID-19. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2021, 21, 553-558.	1.1	17
285	Treatment Options for COVID-19-Related Guillain-Barré Syndrome. <i>Neurologist</i> , 2021, 26, 196-224.	0.4	7



#	ARTICLE	IF	CITATIONS
286	Mesenchymal Stromal Cells: Potential Option for COVID-19 Treatment. <i>Pharmaceutics</i> , 2021, 13, 1481.	2.0	3
287	SARS-CoV-2 vaccination in patients with solid tumors or hematological malignancies: Is the pandemic over for fully vaccinated patients?. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 221-223.	0.3	1
288	Convalescent plasma for SARS-CoV-2 infection: Win or Learn. <i>European Respiratory Journal</i> , 2021, , 2102076.	3.1	2
289	COVID-19 and oral diseases: Assessing manifestations of a new pathogen in oral infections. <i>International Reviews of Immunology</i> , 2022, 41, 423-437.	1.5	12
290	A Multicenter, Prospective, Observational, Cohort-Controlled Study of Clinical Outcomes Following Coronavirus Disease 2019 (COVID-19) Convalescent Plasma Therapy in Hospitalized Patients With COVID-19. <i>Clinical Infectious Diseases</i> , 2022, 75, e466-e472.	2.9	9
291	A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	100
293	Neglected roles of IgG Fc-binding protein secreted from airway mucin-producing cells in protecting against SARS-CoV-2 infection. <i>Innate Immunity</i> , 2021, 27, 423-436.	1.1	6
294	Efficacy and safety of current medications for treating severe and non-severe COVID-19 patients: an updated network meta-analysis of randomized placebo-controlled trials. <i>Aging</i> , 2021, 13, 21866-21902.	1.4	17
295	Clinical trials with antiviral drugs against COVID-19: some progress and many shattered hopes. <i>Environmental Microbiology</i> , 2021, 23, 6364-6376.	1.8	12
296	Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. <i>Nature Medicine</i> , 2021, 27, 2012-2024.	15.2	206
298	Immunotherapy Summary for Cytokine Storm in COVID-19. <i>Frontiers in Pharmacology</i> , 2021, 12, 731847.	1.6	9
299	Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent Plasma. <i>Viruses</i> , 2021, 13, 1844.	1.5	5
300	Efficacy of COVID-19 Treatments: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Public Health</i> , 2021, 9, 729559.	1.3	27
301	Emerging Pulmonary Infections in Clinical Practice. <i>Advances in Clinical Radiology</i> , 2021, 3, 103-124.	0.1	0
302	A Hemagglutination-Based Semiquantitative Test for Point-of-Care Determination of SARS-CoV-2 Antibody Levels. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0118621.	1.8	6
303	Global public health security and justice for vaccines and therapeutics in the COVID-19 pandemic. <i>EClinicalMedicine</i> , 2021, 39, 101053.	3.2	45
304	Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis. <i>BMJ, The</i> , 2021, 374, n2231.	3.0	59
305	Analysis of SARS-CoV-2 reverse transcription-quantitative polymerase chain reaction cycle threshold values vis-À-vis anti-SARS-CoV-2 antibodies from a high incidence region. <i>International Journal of Infectious Diseases</i> , 2021, 110, 114-122.	1.5	3

#	ARTICLE	IF	CITATIONS
307	An internally validated prediction model for critical COVID-19 infection and intensive care unit admission in symptomatic pregnant women. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 226, 403.e1-403.e13.	0.7	23
308	Convalescent plasma therapy in B-cell-depleted and B-cell sufficient patients with life-threatening COVID-19 – A case series. <i>Transfusion and Apheresis Science</i> , 2021, , 103278.	0.5	5
309	Use of Outpatient-Derived COVID-19 Convalescent Plasma in COVID-19 Patients Before Seroconversion. <i>Frontiers in Immunology</i> , 2021, 12, 739037.	2.2	3
310	Hospital transfusion service operations during the SARS-CoV-2 pandemic: Lessons learned from the AABB hospital survey in preparation for the next infectious disease outbreak. <i>Transfusion</i> , 2021, 61, 3129-3138.	0.8	9
311	The Effectiveness of Convalescent Plasma for the Treatment of Novel Corona Virus Disease 2019: A Systematic Review and Meta-Analysis. <i>Frontiers in Medicine</i> , 2021, 8, 641429.	1.2	9
312	Safety and Efficacy of Convalescent Plasma in COVID-19: An Overview of Systematic Reviews. <i>Diagnostics</i> , 2021, 11, 1663.	1.3	19
313	Antibody Response against SARS-CoV-2 Infection: Implications for Diagnosis, Treatment and Vaccine Development. <i>International Reviews of Immunology</i> , 2022, 41, 393-413.	1.5	13
315	COVID-19 and X-linked agammaglobulinemia (XLA) – insights from a monogenic antibody deficiency. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2021, 21, 525-534.	1.1	22
316	Sequential dosing of convalescent COVID-19 plasma with significant temporal clinical improvements in a persistently SARS-COV-2 positive patient. <i>Transfusion and Apheresis Science</i> , 2021, 60, 103180.	0.5	0
317	The prognostic value of cardiac troponin for 60 day mortality and major adverse events in COVID-19 patients. <i>Cardiovascular Pathology</i> , 2021, 55, 107374.	0.7	2
318	A combined strategy to detect plasma samples reliably with high anti-SARS-CoV-2 neutralizing antibody titers in routine laboratories. <i>Journal of Clinical Virology</i> , 2021, 144, 104984.	1.6	7
319	Novel treatments and trials in COVID-19. , 2022, , 109-120.		1
320	Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
321	Effectiveness of Convalescent Plasma Therapy in Severe or Critically Ill COVID-19 Patients: A Retrospective Cohort Study. <i>Yonsei Medical Journal</i> , 2021, 62, 799.	0.9	2
322	An update of anti-viral treatment of COVID-19. <i>Turkish Journal of Medical Sciences</i> , 2021, 51, 3372-3390.	0.4	55
323	Clinical effectiveness of convalescent plasma in hospitalized patients with COVID-19: a systematic review and meta-analysis. <i>Therapeutic Advances in Respiratory Disease</i> , 2021, 15, 175346662110280.	1.0	2
324	Case Management of COVID-19 (Secondary Version). <i>JMA Journal</i> , 2021, 4, 191-197.	0.6	18
326	Donors for SARS-CoV-2 Convalescent Plasma for a Controlled Clinical Trial: Donor Characteristics, Content and Time Course of SARS-CoV-2 Neutralizing Antibodies. <i>Transfusion Medicine and Hemotherapy</i> , 2021, 48, 137-147.	0.7	21



#	ARTICLE	IF	CITATIONS
327	Covid-19: Arthritis drugs improve survival in intensive care patients, shows study. <i>BMJ, The</i> , 2021, 372, n61.	3.0	11
328	Development and application of therapeutic antibodies against COVID-19. <i>International Journal of Biological Sciences</i> , 2021, 17, 1486-1496.	2.6	47
331	SARS-CoV-2 mechanisms of action and impact on human organism, risk factors and potential treatments. An exhaustive survey. <i>International Journal of Transgender Health</i> , 2021, 14, 894-947.	1.1	0
332	Polyclonal F(ab <sup>™</sup> ) <sub>2</sub> fragments of equine antibodies raised against the spike protein neutralize SARS-CoV-2 variants with high potency. <i>IScience</i> , 2021, 24, 103315.	1.9	23
333	Mortality risk factors of COVID-19 infection in kidney transplantation recipients: a systematic review and meta-analysis of cohorts and clinical registries. <i>Scientific Reports</i> , 2021, 11, 20073.	1.6	40
334	Active surveillance of serious adverse events following transfusion of COVID-19 convalescent plasma. <i>Transfusion</i> , 2021, , .	0.8	4
335	An affinity-enhanced, broadly neutralizing heavy chain-only antibody protects against SARS-CoV-2 infection in animal models. <i>Science Translational Medicine</i> , 2021, 13, eabi7826.	5.8	41
336	Mechanisms of SARS-CoV-2 entry into cells. <i>Nature Reviews Molecular Cell Biology</i> , 2022, 23, 3-20.	16.1	1,532
337	Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1690.	3.8	169
338	Convalescent Plasma for Patients Hospitalized With Coronavirus Disease 2019: A Meta-Analysis With Trial Sequential Analysis of Randomized Controlled Trials. <i>Transfusion Medicine Reviews</i> , 2022, 36, 16-26.	0.9	11
339	COVID-19 convalescent plasma. <i>Blood</i> , 2022, 140, 196-207.	0.6	31
340	Rapid and Successful Implementation of a COVID-19 Convalescent Plasma Programme-The South African Experience. <i>Viruses</i> , 2021, 13, 2050.	1.5	5
341	Convalescent plasma treatment for patients of 80 years and older with COVID-19 pneumonia. <i>BMC Geriatrics</i> , 2021, 21, 566.	1.1	3
342	COVID-19 Advanced Care. <i>Journal of Personalized Medicine</i> , 2021, 11, 1082.	1.1	1
343	Complicated and persistent severe COVID-19 pneumonia in a recipient of allogeneic haematopoietic stem cell transplant. <i>BMJ Case Reports</i> , 2021, 14, e245992.	0.2	4
344	Elevated Humoral Immune Response to SARS-CoV-2 at High Altitudes Revealed by an Anti-RBD In-House ELISA. <i>Frontiers in Medicine</i> , 2021, 8, 720988.	1.2	5
345	Dynamics of SARS-CoV-2-specific antibodies among COVID19 biobank donors in Argentina. <i>Heliyon</i> , 2021, 7, e08140.	1.4	7
347	COVID-19 in a patient with Good's syndrome and in 13 patients with common variable immunodeficiency. <i>Clinical Immunology Communications</i> , 2021, 1, 20-24.	0.5	2

#	ARTICLE	IF	CITATIONS
348	Serological anti-SARS-CoV-2 neutralizing antibodies association to live virus neutralizing test titers in COVID-19 paucisymptomatic/symptomatic patients and vaccinated subjects. <i>International Immunopharmacology</i> , 2021, 101, 108215.	1.7	20
349	Serology-based therapeutic strategy in SARS-CoV-2-infected patients. <i>International Immunopharmacology</i> , 2021, 101, 108214.	1.7	2
350	Prevention and Treatment of SARS-CoV2 Infection in People Living with HIV: The Need for Specific Data. <i>Infectious Diseases and Therapy</i> , 2021, , 1.	1.8	6
351	Immune interventions in COVID-19: a matter of time?. <i>Mucosal Immunology</i> , 2022, 15, 198-210.	2.7	14
352	Immunomodulatory therapies for the treatment of SARS-CoV-2 infection: an update of the systematic literature review to inform EULAR points to consider. <i>RMD Open</i> , 2021, 7, e001899.	1.8	8
353	COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. <i>Lancet Haematology</i> ,the, 2021, 8, e934-e946.	2.2	46
354	Update on and Future Directions for Use of Anti-SARS-CoV-2 Antibodies: National Institutes of Health Summit on Treatment and Prevention of COVID-19. <i>Annals of Internal Medicine</i> , 2022, 175, 119-126.	2.0	13
355	Guidelines on the treatment with integrated traditional Chinese medicine and western medicine for severe coronavirus disease 2019. <i>Pharmacological Research</i> , 2021, 174, 105955.	3.1	15
356	Effects of Severe Acute Respiratory Syndrome Coronavirus 2 Strain Variation on Virus Neutralization Titers: Therapeutic Use of Convalescent Plasma. <i>Journal of Infectious Diseases</i> , 2022, 225, 971-976.	1.9	5
357	Convalescent Plasma Improves Overall Survival in Patients with B-Cell Lymphoid Malignancies and COVID-19: A Longitudinal Cohort and Propensity Score Analysis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
358	The concentrated antibody from convalescent plasma balanced the dysfunctional immune responses in patients with critical COVID-19. <i>Clinical and Translational Medicine</i> , 2021, 11, e571.	1.7	1
359	SARS-CoV-2 monoclonal antibody combination therapy in patients with COVID-19 and primary antibody deficiency. <i>Journal of Infectious Diseases</i> , 2021, , .	1.9	11
360	Antibody Dynamics and Durability in Coronavirus Disease-19. <i>Clinics in Laboratory Medicine</i> , 2022, 42, 85-96.	0.7	16
361	COVID-19 in patients with CLL: how can we change the odds?. <i>Blood</i> , 2021, 138, 1652-1653.	0.6	1
362	SARS-CoV-2 and HIV-1: Should HIV-1-Infected Individuals in Sub-Saharan Africa Be Considered a Priority Group for the COVID-19 Vaccines?. <i>Frontiers in Immunology</i> , 2021, 12, 797117.	2.2	4
363	Use of Convalescent Plasma in the Management of COVID-19. <i>Missouri Medicine</i> , 2021, 118, 118.	0.3	0
364	Inflammation in COVID-19: from pathogenesis to treatment. <i>International Journal of Clinical and Experimental Pathology</i> , 2021, 14, 831-844.	0.5	6
365	CROI 2021: Advances in Antiretroviral Therapy for HIV and Antiviral Therapy for COVID-19. <i>Topics in Antiviral Medicine</i> , 2021, 29, 361-378.	0.1	1

#	ARTICLE	IF	CITATIONS
366	Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2. <i>Theranostics</i> , 2022, 12, 1-17.	4.6	6
367	COVID-19 & Heart. , 2022, , 105-116.		0
368	Current Updates on Covid-19 Vaccine Research and an Overview of Therapeutic Drug Research. <i>Biosciences, Biotechnology Research Asia</i> , 2021, 18, 439-457.	0.2	0
369	What have we learned from the first to the second wave of COVID-19 pandemic? An international survey from the ESCMID Study Group for Infection in the Elderly (ESGIE) group. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2022, 41, 281-288.	1.3	8
370	Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination. <i>Emerging Microbes and Infections</i> , 2022, 11, 18-29.	3.0	25
371	SARS-CoV-2 Infection of Rhesus Macaques Treated Early with Human COVID-19 Convalescent Plasma. <i>Microbiology Spectrum</i> , 2021, 9, e0139721.	1.2	15
372	Functional convalescent plasma antibodies and pre-infusion titers shape the early severe COVID-19 immune response. <i>Nature Communications</i> , 2021, 12, 6853.	5.8	41
373	Early Transfusion of Convalescent Plasma Improves the Clinical Outcome in Severe SARS-CoV2 Infection. <i>Infectious Diseases and Therapy</i> , 2022, 11, 293-304.	1.8	11
375	Management of COVID patients with convalescent plasma: Do we have the final word?. <i>European Journal of Internal Medicine</i> , 2022, 95, 13-16.	1.0	3
376	Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials. <i>BMC Infectious Diseases</i> , 2021, 21, 1170.	1.3	46
377	A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	51
378	ESCMID COVID-19 living guidelines: drug treatment and clinical management. <i>Clinical Microbiology and Infection</i> , 2022, 28, 222-238.	2.8	103
379	XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants. <i>Frontiers in Immunology</i> , 2021, 12, 761250.	2.2	7
380	SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin. <i>BioDrugs</i> , 2022, 36, 41-53.	2.2	26
381	Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters. <i>Journal of Virology</i> , 2022, 96, JVI0155121.	1.5	18
382	Virtual Screening and In Silico Interactions Studies for Potential Antivirals and Diagnostics against the Spike protein from the Novel Coronavirus SARS-Cov-2. <i>IOP Conference Series: Materials Science and Engineering</i> , 2021, 1192, 012025.	0.3	0
383	Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia. <i>JAMA Network Open</i> , 2021, 4, e2136246.	2.8	50
384	SARS-CoV-2 antibody changes in patients receiving COVID-19 convalescent plasma from normal and vaccinated donors. <i>Transfusion and Apheresis Science</i> , 2022, 61, 103326.	0.5	10

#	ARTICLE	IF	CITATIONS
385	Effectiveness of convalescent plasma therapy in eight non-intubated coronavirus disease 2019 patients in Indonesia: a case series. <i>Journal of Medical Case Reports</i> , 2021, 15, 564.	0.4	1
386	Coronavirus Disease 2019: Clinics, Treatment, and Prevention. <i>Frontiers in Microbiology</i> , 2021, 12, 761887.	1.5	21
387	Efficacy and safety of convalescent plasma therapy in patients with moderate-to-severe COVID-19: A non-randomized comparative study with historical control in a referral hospital in Indonesia. <i>Journal of Infection and Public Health</i> , 2022, 15, 100-108.	1.9	5
388	Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality. <i>Science Advances</i> , 2021, 7, eabj5629.	4.7	32
390	Regulatory challenges of convalescent plasma collection during the evolving stages of COVID-19 pandemic in the United States. <i>Transfusion</i> , 2022, 62, 483-492.	0.8	2
391	Prevention of viral infections in solid organ transplant recipients in the era of COVID-19: a narrative review. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 663-680.	2.0	0
392	Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in Southern Sweden. <i>BMC Research Notes</i> , 2021, 14, 440.	0.6	21
393	Discrepant Antigen-specific Antibody Responses Causing SARS-CoV-2 Persistence in a Patient Receiving B-cell-targeted Therapy with Rituximab. <i>Internal Medicine</i> , 2021, 60, 3827-3831.	0.3	8
394	Pharmacokinetics of high-titer anti-SARS-CoV-2 human convalescent plasma in high-risk children. <i>JCI Insight</i> , 2022, 7, .	2.3	12
395	Is SARS-CoV-2 viral clearance in nasopharyngeal swabs an appropriate surrogate marker for clinical efficacy of neutralising antibody-based therapeutics?. <i>Reviews in Medical Virology</i> , 2022, 32, e2314.	3.9	7
396	A comparison between virus- versus patients-centred therapeutic attempts to reduce COVID-19 mortality. <i>Emerging Microbes and Infections</i> , 2021, 10, 2256-2263.	3.0	6
397	Factors That Shape Women's Physical Activity: Development of the Reasons to Participate in Physical Activity Scale (RPPAS). <i>Healthcare (Switzerland)</i> , 2022, 10, 94.	1.0	1
399	Effect of convalescent plasma as complementary treatment in patients with moderate COVID-19 infection. <i>Transfusion Medicine</i> , 2022, 32, 153-161.	0.5	14
400	Concerns about estimating relative risk of death associated with convalescent plasma for COVID-19. <i>Nature Medicine</i> , 2022, 28, 51-52.	15.2	4
401	HIV and Aging in the Era of ART and COVID-19: Symposium Overview. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 89, S3-S9.	0.9	0
402	Convalescent plasma treatment in severely immunosuppressed patients hospitalized with COVID-19: an observational study of 28 cases. <i>Infectious Diseases</i> , 2022, 54, 283-291.	1.4	17
403	Plasma therapy: a passive resistance against the deadliest. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-10.	1.4	5
404	Estudo dos fármacos selecionados em ensaios clínicos na terapia farmacológica da COVID-19. <i>Research, Society and Development</i> , 2022, 11, e11611124445.	0.0	0

#	ARTICLE	IF	CITATIONS
406	COVID-19 IN CHILDREN AND ADOLESCENT: CHARACTERISTICS AND SPECIFICITIES IN IMMUNOCOMPETENT AND ONCOHEMATOLOGICAL PATIENTS. Mediterranean Journal of Hematology and Infectious Diseases, 2022, 14, e2022009.	0.5	5
407	COVID-19 and the impact on blood availability and transfusion practices in low- and middle-income countries. Transfusion, 2022, 62, 336-345.	0.8	7
408	Therapeutic role of immunomodulators during the COVID-19 pandemic – a narrative review. Postgraduate Medicine, 2022, 134, 160-179.	0.9	9
409	A possible dose-response equation: Viral load after plasma infusion in COVID-19 patients and anti-SARS-CoV-2 antibody titers in convalescent plasma. Transfusion Medicine, 2022, , e12852.	0.5	0
410	Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy. International Journal of Biological Sciences, 2022, 18, 459-472.	2.6	65
411	Pulmonary Aspects of COVID-19. Annual Review of Medicine, 2022, 73, 81-93.	5.0	8
412	Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial. Lancet, The, 2022, 399, 530-540.	6.3	48
413	Coagulation profile of human COVID-19 convalescent plasma. Scientific Reports, 2022, 12, 637.	1.6	4
414	Experience with COVID-19 convalescent plasma provides vital guidance to future pandemics. Transfusion, 2022, 62, 681-684.	0.8	6
416	Age-associated SARS-CoV-2 breakthrough infection and changes in immune response in a mouse model. Emerging Microbes and Infections, 2022, 11, 368-383.	3.0	33
417	High-dose immunoglobulins from convalescent donors for patients hospitalised with COVID-19. Lancet, The, 2022, 399, 497-499.	6.3	3
418	A Peek into Pandora's Box: COVID-19 and Neurodegeneration. Brain Sciences, 2022, 12, 190.	1.1	9
419	A guide to immunotherapy for COVID-19. Nature Medicine, 2022, 28, 39-50.	15.2	206
420	The EHA Research Roadmap: Transfusion Medicine. HemaSphere, 2022, 6, e670.	1.2	2
421	Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19. , 2022, 1, .		77
422	Lessons learned from the use of convalescent plasma for the treatment of COVID-19 and specific considerations for immunocompromised patients. Transfusion and Apheresis Science, 2022, 61, 103355.	0.5	9
423	A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19. Nature Communications, 2022, 13, 383.	5.8	39
424	The Role of Disease Severity and Demographics in the Clinical Course of COVID-19 Patients Treated With Convalescent Plasma. Frontiers in Medicine, 2021, 8, 707895.	1.2	3

#	ARTICLE	IF	CITATIONS
425	Standardized two-step testing of antibody activity in COVID-19 convalescent plasma. <i>IScience</i> , 2022, 25, 103602.	1.9	6
426	B cell receptor repertoire kinetics after SARS-CoV-2 infection and vaccination. <i>Cell Reports</i> , 2022, 38, 110393.	2.9	29
427	Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysis. <i>Leukemia</i> , 2022, 36, 1025-1034.	3.3	48
428	SARS-CoV-2 Infection and Lung Regeneration. <i>Clinical Microbiology Reviews</i> , 2022, 35, e0018821.	5.7	24
429	COVID-19 in the Immunocompromised Host, Including People with Human Immunodeficiency Virus. <i>Infectious Disease Clinics of North America</i> , 2022, 36, 397-421.	1.9	7
430	Convalescent plasma may not be an effective treatment for severe and critically ill covid-19 patients: A Systematic Review & Meta-Analysis of Randomized Controlled Trials. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2022, 53, 51-60.	0.8	7
431	High-Dose Convalescent Plasma for Treatment of Severe COVID-19. <i>Emerging Infectious Diseases</i> , 2022, 28, 548-555.	2.0	26
432	The CTSA University of Texas Health Science Center (UTHSC) Northeast Tyler and Rio Grande Valley Success Story: How Rural, Underserved Academic Communities Rapidly Built a Robust Engine for Collaborative COVID-19 Clinical Research. <i>Journal of Health Care for the Poor and Underserved</i> , 2022, 33, 517-527.	0.4	0
433	Low neutralizing antibody titers after asymptomatic or non-severe SARS-CoV-2 infection over a 6-month assessment period. <i>Journal of Infection</i> , 2022, 84, 722-746.	1.7	3
434	A randomized, controlled, feasibility study of RD-19 in subjects with mild-to-moderate COVID-19 in the outpatient setting. <i>Clinical and Translational Science</i> , 2022, 15, 1291-1303.	1.5	4
435	A Randomized Trial of Sitagliptin and Spironolactone With Combination Therapy in Hospitalized Adults With COVID-19. <i>Journal of the Endocrine Society</i> , 2022, 6, bvac017.	0.1	15
436	Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection. <i>Nature Microbiology</i> , 2022, 7, 423-433.	5.9	78
437	WHO covid-19 drugs guideline: reconsider using convalescent plasma. <i>BMJ, The</i> , 2022, 376, o295.	3.0	6
438	Evidence-based dosing of convalescent plasma for COVID-19 in future trials. <i>Clinical Microbiology and Infection</i> , 2022, 28, 667-671.	2.8	16
439	Convalescent plasma in outpatients with COVID-19. <i>Lancet Respiratory Medicine</i> , 2022, 10, 226-228.	5.2	9
440	Timing of convalescent plasma administration and 28-day mortality in COVID-19 pneumonia. <i>Journal of Investigative Medicine</i> , 2022, 70, 1258-1264.	0.7	7
441	Convalescent Plasma Treatment in Patients with Covid-19: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2022, 13, 817829.	2.2	23
442	High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. <i>Lancet Respiratory Medicine</i> , 2022, 10, 278-288.	5.2	61



#	ARTICLE	IF	CITATIONS
443	Therapeutic Options for Coronavirus Disease 2019 (COVID-19): Where Are We Now?. <i>Current Infectious Disease Reports</i> , 2021, 23, 28.	1.3	5
446	Passive immune therapies: another tool against COVID-19. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 628-641.	0.9	9
447	Pharmacological treatment of COVID-19: an opinion paper. <i>Revista Espanola De Quimioterapia</i> , 2022, 35, 115-130.	0.5	47
448	Safety of convalescent plasma therapy for COVID-19 patients and analysis of viral kinetics: a single-center, open-label, single-arm, interventional study in Japan. <i>GHM Open</i> , 2022, 2, 38-43.	0.1	4
449	Dominant CD8+ T Cell Nucleocapsid Targeting in SARS-CoV-2 Infection and Broad Spike Targeting From Vaccination. <i>Frontiers in Immunology</i> , 2022, 13, 835830.	2.2	19
450	SARS-CoV-2 and Coronavirus Disease Mitigation: Treatment Options, Vaccinations and Variants. <i>Pathogens</i> , 2022, 11, 275.	1.2	9
451	Is Better Standardization of Therapeutic Antibody Quality in Emerging Diseases Epidemics Possible?. <i>Frontiers in Immunology</i> , 2022, 13, 816159.	2.2	3
453	Convalescent Plasma for Preventing Critical Illness in COVID-19: a Phase 2 Trial and Immune Profile. <i>Microbiology Spectrum</i> , 2022, 10, e0256021.	1.2	6
455	Harmonization of Determination of SARS-CoV-2 Antibodies: Is It Always Possible?. <i>Diagnostics</i> , 2022, 12, 483.	1.3	1
456	Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial). <i>Scientific Reports</i> , 2022, 12, 2552.	1.6	23
457	Stratification of hospitalized COVID-19 patients into clinical severity progression groups by immuno-phenotyping and machine learning. <i>Nature Communications</i> , 2022, 13, 915.	5.8	32
458	Antibody attributes that predict the neutralization and effector function of polyclonal responses to SARS-CoV-2. <i>BMC Immunology</i> , 2022, 23, 7.	0.9	6
459	Ofelecin i mi Vlaplinâ€™ Volume II: Immunity Following Infection or mRNA Vaccination, Drug Therapies and Non-Pharmacological Management at Post-Two Years SARS-CoV-2 Pandemic. <i>Medicina (Lithuania)</i> , 2022, 58, 309.	0.8	4
460	COVID-19 and Chagas Disease in Buenos Aires, Argentina. <i>Frontiers in Tropical Diseases</i> , 2022, 2, .	0.5	1
461	The fossilization of randomized clinical trials. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	8
462	Use of Early Donated COVID-19 Convalescent Plasma Is Optimal to Preserve the Integrity of Lymphatic Endothelial Cells. <i>Pharmaceuticals</i> , 2022, 15, 365.	1.7	2
463	The Quality of Anti-SARS-CoV-2 T Cell Responses Predicts the Neutralizing Antibody Titer in Convalescent Plasma Donors. <i>Frontiers in Public Health</i> , 2022, 10, 816848.	1.3	6
464	COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes. <i>Clinical Microbiology Reviews</i> , 2022, 35, e0020021.	5.7	64

#	ARTICLE	IF	CITATIONS
465	Early Outpatient Treatment for Covid-19 with Convalescent Plasma. <i>New England Journal of Medicine</i> , 2022, 386, 1700-1711.	13.9	194
467	Early administration of COVID-19 convalescent plasma with high titer antibody content by live viral neutralization assay is associated with modest clinical efficacy. <i>American Journal of Hematology</i> , 2022, 97, 770-779.	2.0	9
468	Awaiting a cure for COVID-19: therapeutic approach in patients with different severity levels of COVID-19. <i>Infezioni in Medicina</i> , 2022, 30, 11-21.	0.7	3
469	Convalescent plasma in COVID-19: renewed focus on the timing and effectiveness of an old therapy. <i>Blood Research</i> , 2022, 57, 6-12.	0.5	3
470	Efficacy of early transfusion of convalescent plasma with high titer SARS-CoV-2 neutralizing antibodies in hospitalized patients with COVID-19. <i>Transfusion</i> , 2022, 62, 974-981.	0.8	9
471	A efetividade do plasma convalescente no tratamento da COVID-19: revisÃ£o sistemÃtica. <i>Research, Society and Development</i> , 2022, 11, e21811426877.	0.0	0
472	The Fragility of Statistically Significant Results in Randomized Clinical Trials for COVID-19. <i>JAMA Network Open</i> , 2022, 5, e222973.	2.8	16
473	Caring for older adults during the COVID-19 pandemic. <i>Clinical Microbiology and Infection</i> , 2022, 28, 785-791.	2.8	21
475	High-cited favorable studies for COVID-19 treatments ineffective in large trials. <i>Journal of Clinical Epidemiology</i> , 2022, 148, 1-9.	2.4	4
476	Convalescent plasma therapy in patients with severe COVID-19, A single-arm, retrospective study. <i>Microbial Pathogenesis</i> , 2022, 165, 105482.	1.3	1
477	How do I implement an outpatient program for the administration of convalescent plasma for COVID-19?. <i>Transfusion</i> , 2022, , .	0.8	13
479	Asymptomatic COVID-19 in the elderly: dementia and viral clearance as risk factors for disease progression.. <i>Gates Open Research</i> , 0, 5, 143.	2.0	5
480	Treatment of severe COVID-19 patients with either low- or high-volume of convalescent plasma versus standard of care: A multicenter Bayesian randomized open-label clinical trial (COOP-COVID-19-MCTI). <i>The Lancet Regional Health Americas</i> , 2022, 10, 100216.	1.5	7
481	COVID-19 convalescent plasma: Evolving strategies for serological screening in France. <i>Vox Sanguinis</i> , 2022, 117, 606-610.	0.7	5
482	Prolonged COVID-19 infection in a child with lymphoblastic non-Hodgkin lymphoma: which is the best management?. <i>Tumori</i> , 2021, , 030089162110678.	0.6	3
483	Case Series: Convalescent Plasma Therapy for Patients with COVID-19 and Primary Antibody Deficiency. <i>Journal of Clinical Immunology</i> , 2022, 42, 253-265.	2.0	19
485	COVID-19 Antibody Detection and Assay Performance Using Red Cell Agglutination. <i>Microbiology Spectrum</i> , 2021, 9, e0083021.	1.2	3
486	Epidemiological Characteristics of Hospitalized Patients with Moderate versus Severe COVID-19 Infection: A Retrospective Cohort Single Centre Study. <i>Diseases (Basel, Switzerland)</i> , 2022, 10, 1.	1.0	4



#	ARTICLE	IF	CITATIONS
487	Immunological effects of convalescent plasma therapy for coronavirus: a scoping review. <i>BMC Infectious Diseases</i> , 2021, 21, 1278.	1.3	3
491	Real-world treatment patterns and clinical outcomes for inpatients with COVID-19 in the US from September 2020 to February 2021. <i>PLoS ONE</i> , 2021, 16, e0261707.	1.1	5
492	Convalescent plasma for COVID-19: Donor demographic factors associated high neutralising antibody titres. <i>Transfusion Medicine</i> , 2022, 32, 327-337.	0.5	5
493	Early post-infection treatment of SARS-CoV-2 infected macaques with human convalescent plasma with high neutralizing activity had no antiviral effects but moderately reduced lung inflammation. <i>PLoS Pathogens</i> , 2022, 18, e1009925.	2.1	8
494	Specific T-cell responses for guiding treatment with convalescent plasma in severe COVID-19 and humoral immunodeficiency: a case report. <i>BMC Infectious Diseases</i> , 2022, 22, 362.	1.3	6
495	Differential efficacy and safety of anti-SARS-CoV-2 antibody therapies for the management of COVID-19: a systematic review and network meta-analysis. <i>Infection</i> , 2023, 51, 21-35.	2.3	13
496	High-Dose Convalescent Plasma for Treatment of Severe COVID-19 (response). <i>Emerging Infectious Diseases</i> , 2022, 28, 1083-1084.	2.0	0
497	Efficacy of convalescent plasma therapy in the patient with COVID-19: a randomised control trial (COPLA-II trial). <i>BMJ Open</i> , 2022, 12, e055189.	0.8	20
500	Efficacy and Safety of Blood Derivative Therapy for Patients with COVID-19: A Systematic Review and Meta-Analysis. <i>Transfusion Medicine and Hemotherapy</i> , 2022, 49, 388-400.	0.7	3
501	Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9). <i>Leukemia</i> , 2022, 36, 1467-1480.	3.3	63
502	Convalescent Plasma Therapy, Therapeutic Formulations of Repurposed Drugs in 20th Century Epidemics against COVID-19: A Systematic Review. <i>Pharmaceutics</i> , 2022, 14, 1020.	2.0	9
503	Convalescent Plasma for Covid-19 – Making Sense of the Inconsistencies. <i>New England Journal of Medicine</i> , 2022, 386, 1753-1754.	13.9	22
504	Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients. <i>Nature Communications</i> , 2022, 13, 2583.	5.8	25
505	Finding evidence for treatment decisions in a pandemic. <i>Trends in Molecular Medicine</i> , 2022, 28, 536-541.	3.5	3
506	COVID-19 – from emerging global threat to ongoing pandemic crisis. <i>Baylor University Medical Center Proceedings</i> , 2022, 35, 468-475.	0.2	4
507	Development of a cost-effective ovine antibody-based therapy against SARS-CoV-2 infection and contribution of antibodies specific to the spike subunit proteins. <i>Antiviral Research</i> , 2022, 203, 105332.	1.9	2
508	Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	26
509	Management of Relapsed/Refractory ALL With Inotuzumab During COVID-19. A Case Report. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2022, 14, e2022043.	0.5	3

#	ARTICLE	IF	CITATIONS
510	Antibody-mediated neutralization of SARS-CoV-2. <i>Immunity</i> , 2022, 55, 925-944.	6.6	74
511	Reduced neutralizing antibody potency of COVID-19 convalescent vaccinated plasma against SARS-CoV-2 Omicron variant. <i>Vox Sanguinis</i> , 2022, 117, 971-975.	0.7	5
512	Transfusing Convalescent Plasma as Post-Exposure Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Double-Blinded, Phase 2 Randomized, Controlled Trial. <i>Clinical Infectious Diseases</i> , 2023, 76, e477-e486.	2.9	29
513	Efficient and Sustainable Platform for Preparation of a High-Quality Immunoglobulin G as an Urgent Treatment Option During Emerging Virus Outbreaks. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	2
514	Deep mutational engineering of broadly-neutralizing nanobodies accommodating SARS-CoV-1 and 2 antigenic drift. <i>MAbs</i> , 2022, 14, 2076775.	2.6	5
515	Convalescent plasma donors show enhanced cross-reactive neutralizing antibody response to antigenic variants of SARS-CoV-2 following immunization. <i>Transfusion</i> , 2022, 62, 1347-1354.	0.8	9
517	Inflammatory Markers and Auto-Abs to Type I IFNs in COVID-19 Convalescent Plasma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
519	COVID-19 management landscape: A need for an affordable platform to manufacture safe and efficacious biotherapeutics and prophylactics for the developing countries. <i>Vaccine</i> , 2022, 40, 5302-5312.	1.7	5
520	Reinforcement of the Standard Therapy with Two Infusions of Convalescent Plasma for Patients with COVID-19: A Randomized Clinical Trial. <i>Journal of Clinical Medicine</i> , 2022, 11, 3039.	1.0	4
521	European Respiratory Society International Congress 2021: Highlights from the Respiratory clinical care and physiology assembly. <i>ERJ Open Research</i> , 0, , 00710-2021.	1.1	2
522	COVID-19 and its impact on cancer, HIV, and mentally ill patients. , 2022, , 95-137.		1
523	Immune system changes in those with hypertension when infected with SARS-CoV-2. <i>Cellular Immunology</i> , 2022, 378, 104562.	1.4	2
524	COVID-19 convalescent plasma: current status, lessons from the past and future perspectives. <i>Transfusion and Apheresis Science</i> , 2022, , 103487.	0.5	0
525	Convalescent Plasma in Older Adults with COVID-19: A Systematic Review and Meta-Analysis. <i>Annals of Geriatric Medicine and Research</i> , 2022, 26, 208-214.	0.7	1
526	Contemporary Concise Review 2021: COVID-19 and other respiratory infections. <i>Respirology</i> , 0, , .	1.3	1
527	Lessons from SARS-CoV-2 and its variants (Review). <i>Molecular Medicine Reports</i> , 2022, 26, .	1.1	5
528	Impaired Antibody Response Is Associated with Histone-Release, Organ Dysfunction and Mortality in Critically Ill COVID-19 Patients. <i>Journal of Clinical Medicine</i> , 2022, 11, 3419.	1.0	1
529	Production and Quality Assurance of Human Polyclonal Hyperimmune Immunoglobulins Against SARS-CoV-2. <i>Transfusion Medicine Reviews</i> , 2022, 36, 125-132.	0.9	8

#	ARTICLE	IF	CITATIONS
530	Current advances in transfusion medicine 2021: A critical review of selected topics by the AABB Clinical Transfusion Medicine Committee. <i>Transfusion</i> , 0, , .	0.8	0
531	An Exploratory Study of the Differences in Attitudes and Motives Regarding COVID-19 Plasma Donation. <i>Acta Medica Lituanica</i> , 2022, 29, 14.	0.2	1
532	The Efficiency of Convalescent Plasma Therapy in the Management of Critically Ill Patients Infected With COVID-19: A Matched Cohort Study. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
533	Recent advancements and nanotechnological interventions in diagnosis, treatment, and vaccination for COVID-19. , 2022, , 279-303.		0
534	Update on COVID-19 Therapeutics for Solid Organ Transplant Recipients, Including the Omicron Surge. <i>Transplantation</i> , 2022, 106, 1528-1537.	0.5	23
535	SARS-CoV-2 Antibody Longitudinal Profile of Immune Globulin Preparations. <i>Military Medicine</i> , 0, , .	0.4	0
536	How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies. <i>Blood</i> , 2022, 140, 673-684.	0.6	20
537	Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	9
538	Decreased Efficiency of Neutralizing Antibodies from Previously Infected or Vaccinated Individuals against the B.1.617.2 (Delta) SARS-CoV-2 Variant. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	5
539	The burden of SARS-CoV-2 in patients receiving chimeric antigen receptor T cell immunotherapy: everything to lose. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 1155-1162.	2.0	3
540	Decrease in Angiotensin-Converting Enzyme activity but not concentration in plasma/lungs in COVID-19 patients offers clues for diagnosis/treatment. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, 26, 266-278.	1.8	15
541	Analysis of 52â€‰%240 source plasma donors of convalescent <scp>COVID</scp>â€™19 plasma: Sex, ethnicity, and age association with initial antibody levels and rate of dissipation. <i>Journal of Clinical Apheresis</i> , 2022, 37, 449-459.	0.7	5
542	GMP Manufacturing and IND-Enabling Studies of a Recombinant Hyperimmune Globulin Targeting SARS-CoV-2. <i>Pathogens</i> , 2022, 11, 806.	1.2	3
543	Clinical and Virological Response to Convalescent Plasma in a Chronic Lymphocytic Leukemia Patient with COVID-19 Pneumonia. <i>Life</i> , 2022, 12, 1098.	1.1	4
544	The efficiency of convalescent plasma in COVID-19 patients: A systematic review and meta-analysis of randomized controlled clinical trials. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
545	Predictors of mortality in COVID-19 patients treated with convalescent plasma therapy. <i>PLoS ONE</i> , 2022, 17, e0271036.	1.1	4
547	COVID-19 and Adult Acute Leukemia: Our Knowledge in Progress. <i>Cancers</i> , 2022, 14, 3711.	1.7	6
548	Establishing the First COVID-19 Convalescent Plasma Biobank in Jordan. <i>Biopreservation and Biobanking</i> , 2022, 20, 423-428.	0.5	1

#	ARTICLE	IF	CITATIONS
549	Monoclonal Antibodies for Pre- and Postexposure Prophylaxis of COVID-19: Review of the Literature. <i>Pathogens</i> , 2022, 11, 882.	1.2	7
550	Convalescent Plasma for COVID-19: A Single Center Prospective Experience with Serial Antibody Measurements and Review of the Literature. <i>Pathogens</i> , 2022, 11, 958.	1.2	0
551	Efficacy and Safety of COVID-19 Treatment Using Convalescent Plasma Transfusion: Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 10622.	1.2	3
552	Rethinking the role of COVID-19 convalescent plasma in the critically ill. <i>Transfusion and Apheresis Science</i> , 2022, , 103521.	0.5	0
553	Clinical Practice Guidelines From the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 Convalescent Plasma. <i>Annals of Internal Medicine</i> , 2022, 175, 1310-1321.	2.0	50
554	Characterization of pathogen-inactivated COVID-19 convalescent plasma and responses in transfused patients. <i>Transfusion</i> , 2022, 62, 1997-2011.	0.8	7
555	Beyond COVID-19 and lessons learned in the United States. <i>Transfusion Medicine</i> , 2023, 33, 6-15.	0.5	7
556	Post-trial follow-up after a randomized clinical trial of COVID-19 convalescent plasma. <i>Gates Open Research</i> , 0, 6, 110.	2.0	1
558	Lack of efficacy of convalescent plasma in COVID-19 patients with concomitant hematological malignancies: An Italian retrospective study. <i>Hematological Oncology</i> , 2022, 40, 857-863.	0.8	11
559	Multi-center matched cohort study of convalescent plasma for hospitalized patients with COVID-19. <i>PLoS ONE</i> , 2022, 17, e0273223.	1.1	4
561	Outpatient convalescent plasma therapy for high-risk patients with early COVID-19: a randomized placebo-controlled trial. <i>Clinical Microbiology and Infection</i> , 2023, 29, 208-214.	2.8	21
562	Incidence of Stroke in Randomized Trials of COVID-19 Therapeutics: A Systematic Review and Meta-Analysis. <i>Stroke</i> , 2022, 53, 3410-3418.	1.0	4
564	Retrospective study shows that early administration of convalescent plasma in hospitalized COVID-19 patients may have a positive effect on disease progression. <i>Health Science Reports</i> , 2022, 5, .	0.6	0
565	Evaluation of a rapid semiquantitative lateral flow assay for the prediction of serum neutralizing activity against SARS-CoV-2 variants. <i>Journal of Clinical Virology</i> , 2022, 155, 105268.	1.6	2
566	Targeted therapy in Coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and vaccine. <i>International Immunopharmacology</i> , 2022, 111, 109161.	1.7	9
567	Convalescent plasma therapy in COVID-19 patients: a non-randomized case-control study with concurrent control. <i>Brazilian Journal of Medical and Biological Research</i> , 0, 55, .	0.7	3
568	<i>Epidemiology and Control: From Principles to Pandemics.</i> , 2022, , 1-80.		0
569	Comparison of safety and efficacy of convalescent plasma with fresh frozen plasma in severe covid-19 patients. <i>Anais Da Academia Brasileira De Ciencias</i> , 2022, , .	0.3	6

#	ARTICLE	IF	CITATIONS
570	Outpatient Management of COVID-19: A Primer for the Dermatologist. <i>Current Dermatology Reports</i> , 2022, 11, 318-327.	1.1	1
571	Antibody response and intra-host viral evolution after plasma therapy in COVID-19 patients pre-exposed or not to B-cell-depleting agents. <i>British Journal of Haematology</i> , 2022, 199, 549-559.	1.2	9
573	Early and out-of-hospital use of COVID-19 convalescent plasma: An international assessment of utilization and feasibility. <i>Vox Sanguinis</i> , 2022, 117, 1202-1210.	0.7	4
574	Efficacy of COVID-19 Convalescent Plasma Based on Antibody Concentration. <i>Advances in Hematology</i> , 2022, 2022, 1-11.	0.6	3
575	Prospects of animal models and their application in studies on adaptive immunity to SARS-CoV-2. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
576	A randomized placebo-controlled trial of convalescent plasma for adults hospitalized with COVID-19 pneumonia. <i>Scientific Reports</i> , 2022, 12, .	1.6	6
577	Multistep screening and selection of COVID-19 convalescent plasma donors at the early stage of the SARS-CoV-2 pandemic: A retrospective analysis. <i>Health Science Reports</i> , 2022, 5, .	0.6	1
578	Failed clinical trials on COVID-19 acute respiratory distress syndrome in hospitalized patients: common oversights and streamlining the development of clinically effective therapeutics. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 995-1015.	1.9	4
579	Convalescent plasma and COVID-19: Time for a second "second look?". <i>Transfusion Medicine</i> , 2023, 33, 16-20.	0.5	6
580	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With Coronavirus Disease 2019 (COVID-19). <i>Clinical Infectious Diseases</i> , 0, , .	2.9	82
581	Care for adults with COVID-19: living guidelines from the National COVID-19 Clinical Evidence Taskforce. <i>Medical Journal of Australia</i> , 2022, 217, 368-378.	0.8	8
582	Efficacy and Safety of Convalescence Plasma Therapy in COVID-19 Patients: A Systematic Review and Meta-Analysis. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-17.	0.5	2
583	Clinical Trial Subgroup Analyses to Investigate Clinical and Immunological Outcomes of Convalescent Plasma Therapy in Severe COVID-19. <i>Mayo Clinic Proceedings Innovations, Quality &amp; Outcomes</i> , 2022, 6, 511-524.	1.2	3
584	Comparative efficacy and safety of pharmacological interventions for severe COVID-19 patients: An updated network meta-analysis of 48 randomized controlled trials. <i>Medicine (United States)</i> , 2022, 101, e30998.	0.4	3
585	SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort. <i>Hematological Oncology</i> , 2023, 41, 128-138.	0.8	6
586	Current Drug Targets (CDT) special issue on Covid-19 and Coagulopathy Fibrinolysis in COVID-19: impact on clot lysis and modulation of inflammation. <i>Current Drug Targets</i> , 2022, 23, .	1.0	3
588	Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients: An Open-Label Phase II Clinical Trial. <i>Life</i> , 2022, 12, 1565.	1.1	1
590	Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources. <i>Nature Communications</i> , 2022, 13, .	5.8	51

#	ARTICLE	IF	CITATIONS
591	Home and Out-of-Hospital Therapy with COVID-19 Convalescent Plasma in Europe. <i>Life</i> , 2022, 12, 1704.	1.1	0
592	Characterization of CCP: Can We Use Past Convalescent Plasma from COVID-19 Patients for Treatment of New Emerging Variants?. <i>Covid</i> , 2022, 2, 1564-1574.	0.7	0
593	Drugs for the prevention and treatment of COVID-19 and its complications: An update on what we learned in the past 2 years. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	8
594	Therapeutic advances in COVID-19. <i>Nature Reviews Nephrology</i> , 2023, 19, 38-52.	4.1	67
595	Efficacy of COVID-HIGIV in animal models of SARS-CoV-2 infection. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
596	On the Need to Determine the Contribution of Anti-Nucleocapsid Antibodies as Potential Contributors to COVID-19 Convalescent Plasma Efficacy. <i>Viruses</i> , 2022, 14, 2378.	1.5	0
597	The Potential Role of Passive Antibody-Based Therapies as Treatments for Monkeypox. <i>MBio</i> , 2022, 13, .	1.8	11
598	Nucleocapsid-specific antibody function is associated with therapeutic benefits from COVID-19 convalescent plasma therapy. <i>Cell Reports Medicine</i> , 2022, 3, 100811.	3.3	11
599	SARS-CoV-2 IgG Levels Allow Predicting the Optimal Time Span of Convalescent Plasma Donor Suitability. <i>Diagnostics</i> , 2022, 12, 2567.	1.3	0
600	One-year follow-up of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	16
601	Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency “ Three consecutive cases and review of the literature. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed )</i> , 2022, 40, 507-516.	0.2	5
602	Convalescent Plasma to Treat COVID-19: A Two-Center, Randomized, Double-Blind Clinical Trial. <i>Life</i> , 2022, 12, 1767.	1.1	2
603	A Comprehensive Review on the Efficacy of Several Pharmacologic Agents for the Treatment of COVID-19. <i>Life</i> , 2022, 12, 1758.	1.1	9
604	Convalescent plasma in hospitalized pediatric and obstetric coronavirus disease 2019 (<sc>COVID</sc>â€19) patients. <i>Pediatrics International</i> , 2022, 64, .	0.2	2
605	Convalescent plasma treatment for SARS-CoV-2 infected high-risk patients: a matched pair analysis to the LEOSS cohort. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
606	COVID-19 convalescent plasma therapy through the lens of the third year of the pandemic. <i>Clinical Microbiology and Infection</i> , 2022, , .	2.8	1
607	Late Treatment for COVID-19 With Convalescent Plasma. <i>Chest</i> , 2022, 162, e283-e284.	0.4	0
608	Comparison of allocation strategies of convalescent plasma to reduce excess infections and mortality from <sc>SARSâ€CoV</sc>â€2 in a <sc>US</sc>â€like population. <i>Transfusion</i> , 2023, 63, 92-103.	0.8	1



#	ARTICLE	IF	CITATIONS
609	Use of convalescent plasma therapy in hospitalised adult patients with non-critical COVID-19: a focus on the elderly from Hungary. <i>GeroScience</i> , 0, .	2.1	1
610	Understanding the parameters guiding the best practice for treating Bâ€cellâ€depleted patients with <scp>COVID</scp>â€19 convalescent plasma therapy. <i>British Journal of Haematology</i> , 2023, 200, .	1.2	2
611	The clinical outcomes of high neutralizing antibodies titer convalescent plasma therapy in early developed severe COVID-19 patients; a caseâ€control study. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2022, 21, .	1.7	2
612	Inflammatory markers and auto-Abs to type I IFNs in COVID-19 convalescent plasma cohort study. <i>EBioMedicine</i> , 2023, 87, 104414.	2.7	7
613	Outpatient Treatment of Confirmed COVID-19: A Living, Rapid Review for the American College of Physicians. <i>Annals of Internal Medicine</i> , 2023, 176, 92-104.	2.0	9
614	Antiviral Treatment of COVID-19 Pneumonia. <i>Clinics in Chest Medicine</i> , 2022, , .	0.8	0
615	Convalescent or standard plasma versus standard of care in the treatment of COVID-19 patients with respiratory impairment: short and long-term effects. AÂthree-arm randomized controlled clinical trial. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	3
616	Outpatient Treatment of Confirmed COVID-19: Living, Rapid Practice Points From the American College of Physicians (Version 1). <i>Annals of Internal Medicine</i> , 2023, 176, 115-124.	2.0	10
617	COVID-19 subphenotypes at hospital admission are associated with mortality: a cross-sectional study. <i>Annals of Medicine</i> , 2023, 55, 12-23.	1.5	3
618	How Protective are Antibodies to SARS-CoV-2, the Main Weapon of the B-Cell Response?. <i>Stem Cell Reviews and Reports</i> , 0, , .	1.7	2
619	A Double-Blind, Randomized, Placebo-Controlled, Phase II Clinical Study To Evaluate the Efficacy and Safety of Camostat Mesylate (DWJ1248) in Adult Patients with Mild to Moderate COVID-19. <i>Antimicrobial Agents and Chemotherapy</i> , 2023, 67, .	1.4	10
621	Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection. <i>Journal of Taibah University Medical Sciences</i> , 2023, 18, 600-638.	0.5	1
622	AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants. <i>European Journal of Cancer</i> , 2023, 181, 102-118.	1.3	2
624	Evaluation of a COVID-19 convalescent plasma program at a U.S. academic medical center. <i>PLoS ONE</i> , 2022, 17, e0277707.	1.1	1
625	Single Center Experience Using Monoclonal COVID-19 Antibodies in the Management of Immunocompromised Patients with COVID-19. <i>Microorganisms</i> , 2022, 10, 2490.	1.6	1
626	Polyvalent human immunoglobulin for infectious diseases: Potential to circumvent antimicrobial resistance. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
627	Learning how to treat coronavirus disease 2019 in hematopoietic stem cell transplant patients. <i>Transplant Infectious Disease</i> , 2023, 25, .	0.7	0
629	Advances and Challenges of the Decade: The Ever-Changing Clinical and Genetic Landscape of Immunodeficiency. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2023, 11, 107-115.	2.0	3

#	ARTICLE	IF	CITATIONS
631	Early Treatment with Monoclonal Antibodies or Convalescent Plasma Reduces Mortality in Non-Vaccinated COVID-19 High-Risk Patients. <i>Viruses</i> , 2023, 15, 119.	1.5	6
632	Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial. <i>Nature Cancer</i> , 0, , .	5.7	14
634	Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	14
635	International multicenter study comparing COVID-19 in patients with cancer to patients without cancer: Impact of risk factors and treatment modalities on survivorship. <i>ELife</i> , 0, 12, .	2.8	3
636	Symptom Duration and Resolution With Early Outpatient Treatment of Convalescent Plasma for Coronavirus Disease 2019: A Randomized Trial. <i>Journal of Infectious Diseases</i> , 2023, 227, 1266-1273.	1.9	1
637	COVID-19 in Older Adults. , 2023, , 1-19.		0
638	Lassa Fever: A Highly Infectious Life-Threatening Viral Disease of Public Health Concern. , 2024, , 427-433.		0
639	Coronavirus Disease 2019 Convalescent Plasma Outpatient Therapy to Prevent Outpatient Hospitalization: A Meta-Analysis of Individual Participant Data From 5 Randomized Trials. <i>Clinical Infectious Diseases</i> , 2023, 76, 2077-2086.	2.9	27
640	Effect of convalescent plasma transfusion on outcomes of coronavirus disease 2019: a meta-analysis with trial sequential analysis. <i>Journal of Anesthesia</i> , 2023, 37, 451-464.	0.7	1
641	Convalescent human IgG, but not IgM, from COVID-19 survivors confers dose-dependent protection against SARS-CoV-2 replication and disease in hamsters. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
642	Too Early to Abandon Convalescent Plasma for Supportive Treatment of COVID-19. <i>Transfusion Medicine and Hemotherapy</i> , 2023, 50, 256-258.	0.7	0
643	The impact of early therapies for COVID-19 on death, hospitalization and persisting symptoms: a retrospective study. <i>Infection</i> , 0, , .	2.3	2
644	Convalescent plasma (hyperimmune immunoglobulin) for COVID-19 management: An update. <i>Process Biochemistry</i> , 2023, 127, 66-81.	1.8	9
645	Demultiplexing Ig repertoires by parallel mRNA/DNA sequencing shows major differential alterations in severe COVID-19. <i>IScience</i> , 2023, 26, 106260.	1.9	1
646	Developing a Bayesian hierarchical model for a prospective individual patient data meta-analysis with continuous monitoring. <i>BMC Medical Research Methodology</i> , 2023, 23, .	1.4	1
647	Convalescent plasma for people with COVID-19: a living systematic review. <i>The Cochrane Library</i> , 2023, , .	1.5	10
648	Frailty Reduces Vaccine Effectiveness Against SARS-CoV-2 Infection: A Test-Negative Case Control Study Using National VA Data. <i>Journal of Nutrition, Health and Aging</i> , 2023, 27, 81-88.	1.5	4
649	Convalescent Plasma Therapy against COVID-19: An update on the changing facets of the ongoing Pandemic. <i>Current Pharmaceutical Biotechnology</i> , 2023, 24, .	0.9	1



#	ARTICLE	IF	CITATIONS
650	Convalescent plasma therapy for coronavirus disease 2019 in ambulatory versus hospitalized patients: Efficacy and risk of thromboembolism. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2023, 7, 100068.	1.0	3
651	Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients With Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2023, 76, 2018-2024.	2.9	25
652	Mid-titer human convalescent plasma administration results in suboptimal prophylaxis against SARS-CoV-2 infection in rhesus macaques. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
653	Outpatient anti-spike monoclonal antibody administration is associated with decreased morbidity and mortality among patients with cancer and COVID-19. <i>Clinical and Experimental Medicine</i> , 2023, 23, 2739-2748.	1.9	3
654	High-Throughput Neutralization and Serology Assays Reveal Correlated but Highly Variable Humoral Immune Responses in a Large Population of Individuals Infected with SARS-CoV-2 in the US between March and August 2020. <i>MBio</i> , 2023, 14, .	1.8	4
655	Use of convalescent plasma in the treatment of COVID-19. <i>Nature Reviews Nephrology</i> , 2023, 19, 271-271.	4.1	2
657	Coronavirus Disease 2019 Convalescent Plasma Reaches the Slope of Enlightenment in the Gartner Hype Cycle. <i>Clinical Infectious Diseases</i> , 2023, 76, 2087-2089.	2.9	1
658	Effectiveness of COVID-19 Convalescent Plasma (CCP) During the Pandemic Era: A Literature Review. <i>Journal of Blood Medicine</i> , 0, Volume 14, 159-187.	0.7	2
659	Reduced Mortality among COVID-19 ICU Patients after Treatment with HemoClear Convalescent Plasma in Suriname. <i>MBio</i> , 0, , .	1.8	2
660	COVID 19 convalescent plasma: Is there still a place for CCP?. <i>Transfusion and Apheresis Science</i> , 2023, 62, 103680.	0.5	3
661	Safety, Tolerability, and Pharmacokinetics of Anti-SARS-CoV-2 Immunoglobulin Intravenous (Human) Investigational Product (COVID-HIGIV) in Healthy Adults: a Randomized, Controlled, Double-Blinded, Phase 1 Study. <i>Antimicrobial Agents and Chemotherapy</i> , 0, , .	1.4	1
662	COVID-19 convalescent plasma boosts early antibody titer and does not influence the adaptive immune response. <i>JCI Insight</i> , 2023, 8, .	2.3	3
663	Higher plasma levels of thymosin- $\beta$ 1 are associated with a lower waning of humoral response after COVID-19 vaccination: an eight months follow-up study in a nursing home. <i>Immunity and Ageing</i> , 2023, 20, .	1.8	1
664	An update on SARS-CoV-2 immunization and future directions. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	2
666	Subcutaneous anti-COVID-19 hyperimmune immunoglobulin for prevention of disease in asymptomatic individuals with SARS-CoV-2 infection: a double-blind, placebo-controlled, randomised clinical trial. <i>EClinicalMedicine</i> , 2023, 57, 101898.	3.2	1
667	Mechanistic insight into the protective and pathogenic immune-responses against SARS-CoV-2. <i>Molecular Immunology</i> , 2023, 156, 111-126.	1.0	5
668	Effect of Convalescent Plasma Therapy on COVID-19 Patients: A Retrospective Study. <i>Jundishapur Journal of Chronic Disease Care</i> , 2023, 12, .	0.1	0
669	Extreme differences in SARS-CoV-2 viral loads among respiratory specimen types during presumed pre-infectious and infectious periods. , 2023, 2, .		10

#	ARTICLE	IF	CITATIONS
670	Convalescent Plasma Treatment of Patients Previously Treated with B-Cell-Depleting Monoclonal Antibodies Suffering COVID-19 Is Associated with Reduced Re-Admission Rates. <i>Viruses</i> , 2023, 15, 756.	1.5	1
671	Convalescent Plasma Therapy for COVID-19: A Systematic Review and Meta-Analysis on Randomized Controlled Trials. <i>Viruses</i> , 2023, 15, 765.	1.5	11
672	High-titer post-vaccine COVID-19 convalescent plasma for immunocompromised patients during the first omicron surge. <i>Transplant Infectious Disease</i> , 2023, 25, .	0.7	3
673	Coronavirus Disease 2019 Management Strategies in Solid Organ Transplant Recipients. <i>Infectious Disease Clinics of North America</i> , 2023, 37, 475-493.	1.9	1
674	Multi-institutional experience with COVID-19 convalescent plasma in children. <i>Transfusion</i> , 2023, 63, 918-924.	0.8	1
675	Bronchiolitis obliterans syndrome following SARS-CoV-2 infection in an allogeneic hematopoietic stem cell recipient. <i>American Journal of Transplantation</i> , 2023, 23, 844-847.	2.6	0
676	Simple prediction of COVID-19 convalescent plasma units with high levels of neutralization antibodies. <i>Virology Journal</i> , 2023, 20, .	1.4	0
677	The Relationship Between SARS-CoV-2 Neutralizing Antibody Titers and Avidity in Plasma Collected From Convalescent Nonvaccinated and Vaccinated Blood Donors. <i>Journal of Infectious Diseases</i> , 2023, 228, 245-250.	1.9	1
678	COVID-19 convalescent plasma utilization in the United States: data from the National Inpatient Sample. <i>Clinical Infectious Diseases</i> , 0, , .	2.9	0
679	Diagnosis, treatment protocols, and outcomes of liver transplant recipients infected with COVID-19. <i>World Journal of Clinical Cases</i> , 0, 11, 2140-2159.	0.3	1
680	Emerging Pandemic Infectious Disease Threats. , 2023, , 399-411.		0
681	The Effect of Covid Convalescent Plasma on Hospital Stay: A Retrospective Observational Study from a Tertiary Care Hospital in North India. <i>Recent Advances in Anti-Infective Drug Discovery</i> , 2023, 18, .	0.4	0
682	Anticoagulation strategy and safety in critically ill COVID-19 patients: a French retrospective multicentre study. <i>Thrombosis Journal</i> , 2023, 21, .	0.9	0
684	Epidemiology and Control: From Principles to Pandemics. , 2023, , 1-80.		0
696	Clinical Management of Severe Acute Respiratory Infection (SARI) in Elderly Patients Infected with Covid-19. , 2023, , 81-88.		0
701	Passive Immunization. , 2023, , 100-112.e11.		0
702	Coronavirus Vaccines. , 2023, , 248-257.e4.		0
718	Passive antibody therapy in emerging infectious diseases. <i>Frontiers of Medicine</i> , 2023, 17, 1117-1134.	1.5	2

#	ARTICLE	IF	CITATIONS
734	Targets of SARS-CoV-2: therapeutic implications for COVID-19. , 2024, , 3-14.		0
740	COVID-19 in Older Adults. , 2024, , 761-779.		0